$31.60
-0.50-1.56%
Pre-Market: 4:04 AM EDT
Comments
Loading...
Avidity Biosciences Insider Trading Activity | NASDAQ:RNA | Benzinga
Track the latest Avidity Biosciences insider trading activity. Stay informed on recent buys, sells, and market impact for Avidity Biosciences stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Avidity Biosciences Inc Insiders Doing?
At Avidity Biosciences Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 68.61K shares worth $2.13M, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On January 23, 2025, ARTHUR LEVIN, the company's DIRECTOR sold 1.87K shares for $28.6 each.
- On January 23, 2025, Teresa McCarthy, the company's CHIEF HUMAN RESOURCES OFFICER sold 2.96K shares for $28.59 each.
- On January 23, 2025, Michael MacLean, the company's CHIEF FINANCIAL OFFICER sold 3.29K shares for $28.59 each.
Ownership Statistics for Avidity Biosciences Inc
Shares Outstanding
120.212M
Insider Shares Owned
998.742K
Insider Percentage Owned
0.83%
Institutional Shares Held
79.485M
Institutional Percentage Held
66.1%
| Mar 21, 2025 | George Steven Hughes | CHIEF MEDICAL OFFICER | -9.58K | $31.06 | -$297.49K | SELL | -11.62% | 72.85K | Mar 20 | View |
| Mar 21, 2025 | Sarah Boyce | PRESIDENT AND CEO | -31.54K | $31.06 | -$979.56K | SELL | -9.35% | 305.87K | Mar 20 | View |
| Mar 21, 2025 | Michael Flanagan | CHIEF SCIENTIFIC OFFICER | -11.78K | $31.06 | -$365.87K | SELL | -12.81% | 80.19K | Mar 20 | View |
| Mar 21, 2025 | Michael MacLean | CHIEF FINANCIAL OFFICER | -7.93K | $31.06 | -$246.42K | SELL | -7.58% | 96.72K | Mar 20 | View |
| Mar 21, 2025 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | -7.78K | $31.06 | -$241.58K | SELL | -7.41% | 97.13K | Mar 20 | View |
| Mar 12, 2025 | Michael Flanagan | CHIEF SCIENTIFIC OFFICER | 0.00 | $22.18 | -$318.21K | SELL-OPTIONS | 0.00% | 91.97K | Mar 11 | View |
| Mar 04, 2025 | Kathleen Gallagher | CHIEF PROGRAM OFFICER | 0.00 | $22.06 | -$86.44K | SELL-OPTIONS | 0.00% | 50.55K | Mar 03 | View |
| Feb 05, 2025 | Kathleen Gallagher | CHIEF PROGRAM OFFICER | 0.00 | $24.40 | -$91.10K | SELL-OPTIONS | 0.00% | 50.55K | Feb 03 | View |
| Jan 23, 2025 | ARTHUR LEVIN | DIRECTOR | -1.87K | $28.60 | -$53.54K | SELL | -1.28% | 144.33K | Jan 21 | View |
| Jan 23, 2025 | Michael MacLean | CHIEF FINANCIAL OFFICER | -3.29K | $28.59 | -$93.99K | SELL | -3.05% | 104.66K | Jan 21 | View |
| Jan 23, 2025 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | -2.96K | $28.59 | -$84.61K | SELL | -2.74% | 104.91K | Jan 21 | View |
| Jan 23, 2025 | Michael Flanagan | CHIEF SCIENTIFIC OFFICER | -5.67K | $28.60 | -$162.19K | SELL | -5.81% | 91.97K | Jan 21 | View |
| Jan 23, 2025 | Sarah Boyce | PRESIDENT AND CEO | -10.40K | $28.59 | -$297.29K | SELL | -2.99% | 337.41K | Jan 21 | View |
| Jan 23, 2025 | Kathleen Gallagher | CHIEF PROGRAM OFFICER | -9.41K | $29.53 | -$277.91K | SELL | -15.69% | 50.55K | Jan 21 - Jan 22 | View |
| Jan 23, 2025 | George Steven Hughes | CHIEF MEDICAL OFFICER | -3.95K | $28.59 | -$112.86K | SELL | -4.57% | 82.43K | Jan 21 | View |
| Dec 19, 2024 | Michael Flanagan | CSTO | -12.74K | $32.66 | -$416.15K | SELL | -14.92% | 72.65K | Dec 18 | View |
| Dec 19, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | -11.15K | $32.66 | -$364.19K | SELL | -11.85% | 82.94K | Dec 18 | View |
| Dec 19, 2024 | Sarah Boyce | PRESIDENT AND CEO | -31.86K | $32.66 | -$1.04M | SELL | -10.72% | 265.31K | Dec 18 | View |
| Dec 19, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | -11.15K | $32.66 | -$364.19K | SELL | -11.86% | 82.87K | Dec 18 | View |
| Dec 18, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | 0.00 | $23.74 | -$476.11K | SELL-OPTIONS | 0.00% | 94.02K | Dec 16 | View |
| Dec 13, 2024 | Michael Flanagan | CSTO | 0.00 | $29.12 | -$319.12K | SELL-OPTIONS | 0.00% | 85.39K | Dec 11 | View |
| Nov 20, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | 0.00 | $27.68 | -$673.02K | SELL-OPTIONS | 0.00% | 94.02K | Nov 18 | View |
| Nov 20, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $21.68 | -$135.85K | SELL-OPTIONS | 0.00% | 146.20K | Nov 19 | View |
| Nov 08, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | -27.26K | $26.99 | -$4.18M | SELL | -22.46% | 94.09K | Nov 06 | View |
| Oct 23, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $23.94 | -$226.97K | SELL-OPTIONS | 0.00% | 146.20K | Oct 21 | View |
| Oct 17, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | 0.00 | $31.37 | -$857.51K | SELL-OPTIONS | 0.00% | 94.02K | Oct 16 | View |
| Oct 09, 2024 | Tamar Thompson | DIRECTOR | 0.00 | $36.30 | -$520.36K | SELL-OPTIONS | 0.00% | 0.00 | Oct 07 | View |
| Oct 03, 2024 | Michael Flanagan | CSTO | 0.00 | $37.18 | -$1.30M | SELL-OPTIONS | 0.00% | 85.39K | Oct 01 | View |
| Sep 23, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | 36.85K | $44.00 | -$578.74K | GRANT | 64.45% | 94.02K | Sep 19 - Sep 23 | View |
| Sep 23, 2024 | Michael Flanagan | CSTO | 25.00K | $43.95 | -$1.10M | GRANT | 41.40% | 85.39K | Sep 19 - Sep 23 | View |
| Sep 23, 2024 | Sarah Boyce | PRESIDENT AND CEO | 92.12K | $44.00 | -$1.45M | GRANT | 44.93% | 297.16K | Sep 19 - Sep 23 | View |
| Sep 23, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | 38.49K | $44.00 | -$506.44K | GRANT | 46.45% | 121.36K | Sep 19 - Sep 23 | View |
| Sep 20, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $23.49 | -$222.46K | SELL-OPTIONS | 0.00% | 146.20K | Sep 19 | View |
| Sep 13, 2024 | Michael Flanagan | CSTO | -14.89K | $32.82 | -$2.06M | SELL | -19.66% | 60.87K | Sep 11 | View |
| Sep 13, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | 0.00 | $27.31 | -$654.54K | SELL-OPTIONS | 0.00% | 57.17K | Sep 11 | View |
| Aug 21, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $23.21 | -$219.75K | SELL-OPTIONS | 0.00% | 168.70K | Aug 19 | View |
| Aug 07, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $22.30 | -$1.18M | SELL-OPTIONS | 0.00% | 205.04K | Aug 06 | View |
| Jul 23, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $23.13 | -$218.87K | SELL-OPTIONS | 0.00% | 168.70K | Jul 19 | View |
| Jul 11, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $20.59 | -$1.08M | SELL-OPTIONS | 0.00% | 205.04K | Jul 09 | View |
| Jun 21, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $19.42 | -$181.75K | SELL-OPTIONS | 0.00% | 168.70K | Jun 20 | View |
| Jun 20, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | 40.14K | $39.13 | -$385.97K | GRANT | 235.61% | 57.17K | Jun 17 - Jun 18 | View |
| Jun 20, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | 38.77K | $39.13 | -$439.34K | GRANT | 87.93% | 82.86K | Jun 17 - Jun 18 | View |
| Jun 20, 2024 | Sarah Boyce | PRESIDENT AND CEO | 92.93K | $39.13 | -$1.26M | GRANT | 82.88% | 205.04K | Jun 17 - Jun 18 | View |
| Jun 20, 2024 | Michael Flanagan | CSTO | 39.89K | $39.13 | -$395.44K | GRANT | 111.22% | 75.77K | Jun 17 - Jun 18 | View |
| Jun 14, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | 0.00 | $22.27 | -$2.80M | SELL-OPTIONS | 0.00% | 44.09K | Jun 12 | View |
| Jun 14, 2024 | ARTHUR LEVIN | DIRECTOR | -100.00K | $38.07 | -$3.81M | SELL | -37.22% | 168.70K | Jun 12 - Jun 13 | View |
| Jun 14, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $19.93 | -$11.22M | SELL-OPTIONS | 0.00% | 112.12K | Jun 12 - Jun 14 | View |
| Jun 05, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $14.33 | -$733.06K | SELL-OPTIONS | 0.00% | 112.12K | Jun 04 | View |
| May 21, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $15.57 | -$143.28K | SELL-OPTIONS | 0.00% | 268.70K | May 20 | View |
| May 16, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | 0.00 | $18.55 | -$1.46M | SELL-OPTIONS | 0.00% | 44.09K | May 14 | View |
| May 07, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $13.39 | -$680.33K | SELL-OPTIONS | 0.00% | 112.12K | May 07 | View |
| Apr 22, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $12.03 | -$107.92K | SELL-OPTIONS | 0.00% | 268.70K | Apr 19 | View |
| Apr 03, 2024 | ARTHUR LEVIN | DIRECTOR | -20.00K | $27.11 | -$542.21K | SELL | -6.93% | 268.70K | Apr 03 | View |
| Apr 03, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $13.74 | -$700.20K | SELL-OPTIONS | 0.00% | 112.12K | Apr 02 | View |
| Mar 21, 2024 | ARTHUR LEVIN | DIRECTOR | 0.00 | $12.60 | -$113.65K | SELL-OPTIONS | 0.00% | 288.70K | Mar 19 | View |
| Mar 15, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | 0.00 | $16.67 | -$627.96K | SELL-OPTIONS | 0.00% | 44.09K | Mar 13 | View |
| Mar 12, 2024 | ARTHUR LEVIN | DIRECTOR | -2.64K | $11.64 | -$578.02K | SELL | -0.91% | 288.70K | Mar 12 | View |
| Mar 12, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $11.47 | -$2.29M | SELL-OPTIONS | 0.00% | 112.12K | Mar 08 - Mar 12 | View |
| Mar 05, 2024 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $10.69 | -$1.59M | SELL-OPTIONS | 0.00% | 112.12K | Mar 01 | View |
| Jan 23, 2024 | ARTHUR LEVIN | DIRECTOR | -1.86K | $10.13 | -$18.83K | SELL | -0.63% | 291.34K | Jan 22 | View |
| Jan 23, 2024 | Sarah Boyce | PRESIDENT AND CEO | 57.41K | $10.13 | -$51.58K | GRANT | ∞ | 44.01K | Jan 20 - Jan 22 | View |
| Jan 23, 2024 | Michael Flanagan | CSTO | 15.87K | $10.13 | -$41.83K | GRANT | 79.36% | 35.87K | Jan 20 - Jan 22 | View |
| Jan 23, 2024 | Teresa McCarthy | CHIEF HUMAN RESOURCES OFFICER | 14.44K | $10.13 | -$20.92K | GRANT | 555.19% | 17.04K | Jan 20 - Jan 22 | View |
| Jan 23, 2024 | Michael MacLean | CHIEF FINANCIAL OFFICER | 20.88K | $10.13 | -$16.37K | GRANT | ∞ | 16.88K | Jan 20 - Jan 22 | View |
| Mar 17, 2023 | ARTHUR LEVIN | DIRECTOR | 0.00 | $11.63 | -$2.08K | SELL-OPTIONS | 0.00% | 293.20K | Mar 15 | View |
| Feb 15, 2023 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $12.45 | -$224.17K | SELL-OPTIONS | 0.00% | 293.20K | Feb 14 | View |
| Feb 03, 2023 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $12.80 | -$1.16M | SELL-OPTIONS | 0.00% | 53.35K | Feb 01 - Feb 03 | View |
| Jan 17, 2023 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $11.62 | -$207.63K | SELL-OPTIONS | 0.00% | 275.20K | Jan 12 | View |
| Jan 03, 2023 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $11.63 | -$830.97K | SELL-OPTIONS | 0.00% | 1.33K | Dec 29 | View |
| Aug 31, 2022 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $11.48 | -$1.70M | SELL-OPTIONS | 0.00% | 275.20K | Aug 12 - Aug 16 | View |
| Aug 26, 2022 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $12.06 | -$1.08M | SELL-OPTIONS | 0.00% | 0.00 | Aug 24 - Aug 25 | View |
| Aug 17, 2022 | Sarah Boyce | PRESIDENT AND CEO | 0.00 | $11.85 | -$2.12K | SELL-OPTIONS | 0.00% | 0.00 | Aug 15 | View |
| Nov 22, 2021 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.56 | -$666.65K | SELL-OPTIONS | 0.00% | 1.33K | Nov 18 | View |
| Aug 06, 2021 | RTW INVESTMENTS LPRODERICK WONG | MP AND CIO | 800.00K | $18.00 | $14.40M | BUY | 20.03% | 4.79M | Aug 04 | View |
| Jun 28, 2021 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.63 | -$545.22K | SELL-OPTIONS | 0.00% | 1.33K | Jun 24 - Jun 25 | View |
| Jun 22, 2021 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.49 | -$5.30K | SELL-OPTIONS | 0.00% | 1.33K | Jun 17 | View |
| Jun 16, 2021 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | -37.02K | $25.98 | -$961.99K | SELL | -100.00% | 0.00 | Jun 14 - Jun 15 | View |
| Mar 18, 2021 | ARTHUR LEVIN | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.40 | -$123.88K | SELL-OPTIONS | 0.00% | 0.00 | Mar 05 - Mar 16 | View |
| Jun 18, 2020 | Cormorant Asset Management LPBihua ChenCormorant Global Healthcare Master Fund LPCormorant Private Healthcare Fund II LP | — | 2.51M | $18.00 | $5.40M | DERIVATIVE CONVERSION | ∞ | 2.51M | Jun 16 | View |
| Jun 16, 2020 | RTW INVESTMENTS LPRODERICK WONG | — | 4.00M | $18.00 | $17.10M | DERIVATIVE CONVERSION | ∞ | 4.00M | Jun 16 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.